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Abstract
Background Microbial ecosystems that inhabit the human gut form central component of our physiology and metabolism, 
regulating and modulating both health and disease. Changes or disturbances in the composition and activity of this gut 
microbiota can result in altered immunity, inflammation, and even cancer.
Aim To compare the composition and diversity of gut microbiota in stool samples from patient groups based on the site 
of neoplasm in the gastrointestinal tract (GIT) and to assess the possible contribution of the bacterial composition to 
tumorigenesis.
Methods We studied gut microbiota by16S RNA gene sequencing from stool DNA of 83 patients, who were diagnosed with 
different GIT neoplasms, and 13 healthy individuals.
Results As compared to healthy individuals, stools of patients with stomach neoplasms had elevated levels of Enterobac-
teriaceae, and those with rectal neoplasms had lower levels of Bifidobacteriaceae. Lower abundance of Lactobacillaceae 
was seen in patients with colon neoplasms. Abundance of Lactobacillaceae was higher in stools of GIT patients sampled 
after cancer treatment compared to samples collected before start of any treatment. In addition to site-specific differences, 
higher abundances of Ruminococcus, Subdoligranulum and lower abundances of Lachnoclostridium and Oscillibacter were 
observed in overall GIT neoplasms as compared to healthy controls
Conclusion Our study demonstrates that the alterations in gut microbiota vary according to the site of GIT neoplasm. The 
observed lower abundance of two common families, Lactobacillaceae and Bifidobacteriaceae, and the increased abundance 
of Enterobacteriaceae could provide indicators of compromised gut health and potentially facilitate GIT disease monitoring.
Keywords Fecal microbiota · Gastrointestinal neoplasms · 16S rRNA gene sequencing
Introduction
Gut bacteria form a diverse and complex microbial ecosys-
tem that plays a vital role in health and disease [1]. Bacteria 
that belong to the Bacteroidetes and Firmicutes phyla [2, 3] 
form the predominant part of the human gut microbiota, and 
along with Proteobacteria, Actinobacteria, Synergistetes, 
and Fusobacteria constitute the majority of the bacterial spe-
cies found in human gastrointestinal tract (GIT) [4]. Host 
and factors such as age, genotype, local environment, and 
dietary habits exert significant effects on gut microbiota [2, 
3, 5] including the development of different types of GIT 
tumors either through the pro-carcinogenic activities of spe-
cific pathogens, or due to the effect of microbial metabolites 
[6]. Short chain fatty acids and butyrate producing bacteria 
such as Anaerostipes species and, Butyrivibrio species have 
been reported to suppress inflammation and inhibit neo-
plastic changes while other bacterial metabolites such as 
secondary bile acids can induce inflammation, cause DNA 
damage, and enhance carcinogenesis [6, 7]. The colonization 
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and diversity of bacteria in different regions of the GIT can 
vary considerably due to the variation in pH and other physi-
ological factors along the GIT. Moreover, the pathogenic-
ity of bacteria can be different for different regions of the 
GIT. Helicobacter pylori, for instance, has been associated 
with increased incidence of gastric cancer as well as with a 
reduced risk of esophageal cancer [8].
Stool specimens represent a conveniently accessible 
source for investigating the gut microbiota composition. 
Studies based on 16S rRNA gene sequence analysis in 
stool samples have revealed an enrichment of certain bacte-
rial taxa in colorectal cancer (CRC) in conjunction with a 
depletion of others [9–11]. Bacterial species that have been 
reported to be linked to CRC include Streptococcus bovis, 
Bacteroides fragilis, Enterococcus faecalis [9], Clostridium 
septicum [12], Fusobacterium species [13], and Escherichia 
coli [14]. Higher abundances of Fusobacterium nucleatum 
and Bacteroides fragilis have been found to be associated 
with increased risk of adverse outcomes for CRC, while Fae-
calibacterium prausnitzii has been associated with a reduced 
risk [15].
Although the role of H. pylori in gastric carcinoma is 
well established and it is classified by the International 
Agency for Research on Cancer as a human carcinogen 
[1], the knowledge is more limited regarding the diversity 
of other bacterial species and their functional roles in the 
development and progression of stomach carcinoma. We 
here investigated the abundance of gut bacteria in the stool 
specimens of patients with different GIT malignancies in 
order to examine differences in taxonomic composition in 
stool samples based on the location of GIT tumor.
Methods
Patient Population
The study was carried out on stool samples collected from 
83 GIT neoplasia patients and 13 healthy individuals 
(Table 1). The patients were referred to either of the three 
hospitals: Surgical, Meilahti, and Jorvi in Finland. Three of 
the authors (AK, MCH, and SK) collected the stool samples 
from the patients who were referred to them for surgery. All 
the patients and controls were of Finnish origin. Samples 
from 63 patients were obtained at the time of diagnosis, 
before start of any kind of treatment, while samples from 
20 patients (13 with rectum, six with stomach, and one with 
small intestine neoplasms) were obtained after the patients 
had already received treatment, either chemotherapy and/
or radiotherapy. These 20 samples from previously treated 
patients were categorized as a separate group (treated) 
regardless of tumor type/location, while the remaining 63 
samples from non-treated patients were classified into five 
groups according to site of tumor as: stomach, small intes-
tine, pancreas, colon, and rectum (Table 1). Patients with 
stomach neoplasms included seven with GIST, ten of intes-
tinal type, 13 of diffuse type, and five others.
The study was approved by the Hospital District of Hel-
sinki and Uusimaa (HUS) review board (ethical permission 
number 351/13/03/02/2014). Written informed consent was 
obtained from all subjects.
Stool Sample Collection
Stool samples were collected in special tubes, provided in 
the PSP Spin Stool DNA Plus Kit (STRATEC Biomedical 
AG, Germany). One spoon of stool specimen (spoon pro-
vided with the collection tubes) was transferred to the tube 
and mixed thoroughly to obtain a stool homogenate, fol-
lowed by immediate freezing at -20 °C until DNA extraction.
Stool DNA Extraction
DNA was extracted from 1.4 ml of each stool homogenate 
using the PSP Spin Stool DNA Plus Kit (STRATEC Bio-
medical AG, Germany), according to the manufacturer’s 
instructions. DNA was quantified by Qubit 2.0 fluorometer 
(Thermo Fisher Scientific, USA) using the Qubit dsDNA BR 
assay kit. The extracted DNA was then stored at − 20 °C.
16S rRNA Gene Sequencing
Library Preparation
Libraries for sequencing were prepared with Ion 16S 
Metagenomics kit (Thermo Fisher Scientific, USA) accord-
ing to supplied protocol. For each sample, two primer pools 
Table 1  Characteristics of patients studied for stool microbiota analy-
sis
a Treated group includes samples from those patients with gastrointes-
tinal neoplasm, who had already undergone cancer treatment at the 
time of sample collection
b Controls include samples from healthy individuals without any gas-
trointestinal disease
Tumor site Av. age in years (range) Gender Total
Male Female
Controlsb 43.8 (19–65) 3 10 13
Stomach 69.4 (36–98) 17 18 35
Pancreas 62.3 (57–67) 1 2 3
Small intestine 61.5 (39–79) 3 0 3
Colon 74.8 (64–84) 6 7 13
Rectum 73.6 (39–85) 7 2 9
Treateda 66.9 (53–78) 11 9 20
2952 Digestive Diseases and Sciences (2018) 63:2950–2958
1 3
were used to amplify six hypervariable regions (primer 
set V2, V4, V8 and primer set V3, V6–7, and V9) of 16S 
rRNA gene. A volume of 1 µl of each sample DNA (3 ng/µl) 
was used for library preparation, and PCR was performed 
according to the kit’s instructions with 18-cycle PCR pro-
tocol (two reactions/sample). After PCR, the samples were 
purified with Agencourt AMPure XP beads (Beckman Coul-
ter) according to kit’s protocol. Samples were end-repaired, 
purified with Agencourt AMPure XP beads, and the bar-
coded sequencing adapters were ligated following the manu-
facturer’s protocol. After ligation, the libraries were purified 
with Agencourt AMPure XP beads and quantified in the 
TapeStation 4200 instrument (Agilent Technologies). Sam-
ple dilution factors were determined according to TapeSta-
tion results, and libraries were diluted in low TE (26 µM 
Tris, 2.6 µM EDTA) to 10 µM concentration.
Template Preparation and Sequencing
Before sequencing, the template preparation for library pools 
was performed either with Ion OneTouch 2 system (Thermo 
Fisher Scientific) using the Ion PGM™ Hi-Q™ OT2 Kit 
(Thermo Fisher Scientific) or Ion Chef system (Thermo 
Fisher Scientific) using the Ion PGM™ Hi-Q™ Chef Kit fol-
lowing the kit protocols. 2 µl of each 10 pM library was used 
for library pool, and 15–20 libraries were pooled together. 
20 µl of a library pool was mixed with 5 µl of nuclease-free 
water and added to the amplification solution for template 
preparation. After the template preparation, the quality of 
resulting ion spheres was checked with Qubit 3.0 fluorom-
eter (Thermo Fisher Scientific). Following quality check, 
the ion spheres were loaded on an Ion 318™ Chip (Thermo 
Fisher Scientific) and sequenced with Ion PGM system using 
Ion PGM Hi-Q Sequencing kit (Thermo Fisher Scientific) 
according to the protocol provided with the kit.
Data Analysis
Sequencing data from stool samples of 83 patients and 13 
controls were used to create OTU (operational taxonomic 
unit) abundance tables. Between-sample normalization was 
done by rarifying the sequencing counts into even depth with 
the phyloseq R package [16] and subsequently converting 
the rarified read counts to relative abundances. The num-
ber of unique detected taxa included 105 families and 121 
genera.
Gut microbiota community alpha diversity and observed 
richness were analyzed at the family and genus levels using 
the microbiome [17] and vegan R packages [18]. Commu-
nity richness and diversity were quantified by the number 
of unique observed taxa and Shannon index, respectively. 
Significance of the group-level differences was estimated 
with Kruskal–Wallis test. Multiple testing correction was 
done separately for each group of analyses based on the Ben-
jamini–Hochberg FDR correction [19]. The samples were 
grouped based on relative abundances of the taxonomic 
groups using hierarchical clustering (ward.D2 method in 
the hclust function) with Bray–Curtis distance.
Ordination with the unsupervised principal coordinates 
analysis (PCoA), as implemented in the phyloseq R pack-
age [16], is based on Euclidean distance between Hellinger-
transformed abundance profiles [20]. Only the core genera 
or families that were detected in at least 20% of all samples 
were included in the analysis. Significance of the com-
munity-level differences between the groups was assessed 
with PERMANOVA for clr-transformed abundances [21] 
to remove compositionality bias, with the R package com-
positions [22]. The significance for the differences in the 
abundance of individual taxa was assessed with ANCOM 
[23], which has been recently demonstrated to reduce false 
discovery rate (FDR) compared to other alternatives [23, 
24]. The graphs were generated with ggplot2 [25].
Results
The patients were divided into five non-treated and one 
treated groups, and the relative abundances of the genera and 
families in each group were compared to those of the control 
group. The sample similarities (beta diversities) across the 
different groups based on genus-level profiles are illustrated 
with principal coordinates analysis in Fig. 1.
Bacterial Diversity
Alpha diversity (Shannon index) and observed richness did 
not have significant differences between the groups (based 
on location of neoplasm) at the family or genus levels 
Fig. 1  Principal coordinates analysis showing beta diversities across 
different gastrointestinal neoplasm groups based on genus-level bac-
terial profiles
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(adjusted Kruskal–Wallis p = 0.21 for both levels). The 
genus-level pairwise comparison between the groups with 
respect to observed richness and Shannon is shown in Fig. 2.
Beta diversity was not significantly different between the 
controls and the patients, either for the treated or the non-
treated groups. Adjusted p values for pairwise comparisons 
at genus level were not significant in the treated/non-treated, 
treated/control, and non-treated/control pairwise compari-
sons (p > 0.2 in all comparisons).
Comparison of Each Group with the Controls
Family Level
Bacteria belonging to Enterobacteriaceae family were found 
to have significantly higher abundances in stools of patients 
with neoplasms of the stomach or the small intestine than in 
controls. The relative abundance of bacteria from the Lac-
tobacillaceae family was significantly lower in the group of 
patients that had colon or pancreatic neoplasms, while that 
of Acidaminococcaceae was significantly lower than in con-
trols only in colonic neoplasm patients (Table 2). Patients 
with rectal neoplasms had a significantly lower relative 
abundance of Bifidobacteriaceae in their stool samples than 
in controls. Relative abundance of bacterial families in dif-
ferent patient groups is shown in Supplementary Figure 1.
Genus Level
The relative abundances of Ruminococcus and Subdol-
igranulum were significantly higher while those of Lach-
noclostridium and Oscillibacter were significantly lower 
in patients with stomach neoplasms, compared to healthy 
individuals (Table 2). Similar to what was seen in stomach 
neoplasms, the relative abundance of Subdoligranulum was 
also significantly higher and that of Lachnoclostridium and 
Oscillibacter significantly lower in patients with colon neo-
plasms. Moreover, significantly lower relative abundance of 
Lachnoclostridium was also observed in patients with neo-
plasms of the small intestine. Samples from rectal neoplasia 
patients had lower relative abundance of Bifidobacterium, 
whereas samples from pancreatic neoplasia patients showed 
reduced abundance of Parabacteroides as compared to con-
trols. Relative abundance of bacterial genera in different 
patient groups is shown in Supplementary Fig. 2.
Comparison of the Treated Group 
with the Non‑treated Neoplasm Group
Lactobacillaceae at the family level and Lactobacillus at 
the genus level had higher relative abundance in the treated 
group compared to samples from the non-treated group 
(Table 2).
Comparison of All Neoplasms with the Controls
The Enterobacteriaceae family had a significantly higher 
abundance in the non-treated group than in the control 
group. At the genus level, Lachnoclostridium and Oscilli-
bacter had significantly lower abundance, and Ruminococ-
cus, and Subdoligranulum had significantly higher abun-
dance in the non-treated group as compared to the control 
group. Compared to controls, the treated group (irrespective 
of tumor site) had significantly lower abundance of Rumini-
clostridium, Lachnoclostridium and Oscillibacter at the 
genus level.
Fig. 2  Observed richness and alpha diversity of bacteria at the genus 
level. Median relative abundance for the control group is shown by 
dashed line along y-axis. Adjusted p values for pairwise comparisons 
between gastrointestinal neoplasm groups and controls at the bacte-
rial genus level are shown for each group
2954 Digestive Diseases and Sciences (2018) 63:2950–2958
1 3
Discussion
We assessed and compared the stool bacterial profile of 
patients with GIT neoplasms grouped according to the neo-
plasm location, with stomach, colon, and rectum being the 
major groups. In addition to the altered abundances of cer-
tain bacterial taxonomic groups seen in the overall group 
of patients with non-treated GIT neoplasms as compared to 
controls, further differences were observed depending on the 
neoplasm location (Table 2).
At the family level, Enterobacteriaceae had significantly 
higher relative abundance in all non-treated patients, while 
based on the site of neoplasm, significantly higher abun-
dance of Enterobacteriaceae was observed only in patients 
with neoplasms of the stomach or small intestine (Table 2). 
Lower abundances were noted for Lactobacillaceae and 
Acidaminococcaceae in patients with colon neoplasms, 
as well as for Bifidobacteriaceae in rectal neoplasms and 
(Table 2). The family Enterobacteriaceae includes many 
pathogenic bacteria, in addition to commensal ones, and gut 
inflammation is thought to initiate increase in Enterobacte-
riaceae abundance. Previous studies reviewed in Chen et al. 
[26] have shown increase in pathogenic bacteria together 
with depletion of normal healthy gut microbiota associated 
with colorectal cancer. In our study, the increased abundance 
of this family of bacteria was, however, significant only in 
patients with neoplasms of the stomach and small intestine.
Lactobacillaceae and Bifidobacteriaceae are the two 
most prominent families of probiotics that play an impor-
tant role in the maintenance of GIT homeostasis. The loss of 
abundance of these bacteria is reported in CRC, while their 
administration is reported to have a protective effect on CRC 
development as reviewed in Zou et al. [27]. Lactobacilli are 
thought to prevent the development of cancer and cancer cell 
Table 2  Bacteria with 
significant difference in relative 
abundance in stools of patients 
groups based on location of 
neoplasm in the gastrointestinal 
tract compared to healthy 
individuals
a Relative abundance in non-treated patients
b Fold change is not shown where one of the groups has zero average abundance
Patient group Relative abundance 
in patient group (%)
Relative abun-




 Enterobacteriaceae Stomach 5.1 0.2 1.5
 Lactobacillaceae Pancreas 0.0 1.9 NAb
 Enterobacteriaceae Small intestine 5.2 0.2 1.5
 Lactobacillaceae Colon 0.1 1.9 − 1.1
 Acidaminococcaceae Colon 0.1 0.9 − 1.0
 Bifidobacteriaceae Rectum 0.0 0.2 NAb
 Enterobacteriaceae All non-treated 5.5 0.2 1.5
 Bifidobacteriaceae Treated 0.2 0.2 − 0.1
 Lactobacillaceae Treated versus non-treated 1.1 0.7a 0.2
Genus
 Ruminococcus Stomach 2.9 0.8 0.6
 Subdoligranulum Stomach 0.2 0.0 1.4
 Lachnoclostridium Stomach 0.4 0.6 − 0.2
 Oscillibacter Stomach 0.1 0.2 − 0.6
 Parabacteroides Pancreas 0.5 5.0 − 1.0
 Lachnoclostridium Small intestine 0.10 0.6 − 1.0
 Subdoligranulum Colon 0.1 0.0 1.1
 Lachnoclostridium Colon 0.2 0.6 − 0.5
 Oscillibacter Colon 0.0 0.2 − 1.0
 Bifidobacterium Rectum 0.0 0.4 − 1.8
 Ruminococcus All non-treated 2.9 0.8 0.6
 Subdoligranulum All non-treated 0.2 0.0 1.4
 Lachnoclostridium All non-treated 0.4 0.6 − 0.1
 Oscillibacter All non-treated 0.1 0.2 − 0.6
 Ruminiclostridium Treated 0.0 0.4 − 1.7
 Lachnoclostridium Treated 0.3 0.6 − 0.4
 Oscillibacter Treated 0.0 0.2 − 0.7
 Lactobacillus Treated versus non-treated 0.9 0.7a 0.1
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migration and have been reported to inhibit the growth of 
human colon carcinoma cells [28]. A combination of pro-
biotic Bifidobacterium lactis and prebiotic resistant starch 
has been shown to prevent the development of CRC in rats 
and has been proposed as a chemopreventive approach for 
CRC [29].
The majority of previous studies have considered colo-
rectal cancer as a single group, and there is little information 
related to bacterial dysbiosis in the colon and rectal cancers 
separately. In the present study, we found reduced abundance 
of Lactobacillaceae related to neoplastic growth in colon, 
while reduced abundance of Bifidobacteriaceae was related 
to neoplasms of the rectum. Intriguingly, we also observed 
that at the genus level, while alterations in bacteria were 
similar between colon and stomach neoplasms (higher abun-
dance of Subdoligranulum; lower abundance of Lachnoclo-
stridium and Oscillibacter), there were no commonly altered 
bacteria between colon and rectal neoplasms (Fig. 3). This 
again suggests that there is a distinct difference in the effect 
of bacterial dysbiosis on neoplastic growth between colon 
and rectum. Although colorectal tumors are usually consid-
ered similar, there are few marked differences between the 
two types of tumors. At a molecular level, rectal tumors have 
higher rate of aneuploidy, loss of heterozygosity and TP53 
mutations while colon cancers have higher microsatellite 
instability and more frequent CpG island methylator phe-
notype (reviewed in Iacopetta 2002) [30]. Bifidobacterium 
contributes significantly to de novo biosynthesis of folate in 
gut and to folate store in colon [31]. Humans cannot synthe-
size folate and are dependent on external sources (from food 
or bacterial synthesis), and the deficiency of folate can result 
in chromosomal instability [32, 33] and susceptibility for 
childhood leukemia [34]. Reduced levels of Bifidobacterium 
could result in decreased folate levels in the large intestine 
and thus increase the risk of aneuploidies associated with 
rectal neoplasms.
Gut bacteria are most abundant in colon compared to 
other regions of the GIT, and disturbances in bacterial abun-
dances would be expected to associate most closely with 
neoplastic growth located in the colorectal region. However, 
in our study, there were more bacteria genera altered in gas-
tric neoplasms, which are similar to those detected in colon 
neoplasms, than in rectal neoplasms. Interestingly, the bacte-
rial genera associated with gastric or colon neoplasms are 
related to inflammation, or metabolic diseases. Increased 
levels of Ruminococcus and Subdoligranulum have been 
reported in the stools of children with food sensitivity com-
pared to healthy children [35]. Subdoligranulum has been 
Fig. 3  Comparison of differ-
ent gastrointestinal neoplasm 
groups with respect to altered 
relative abundance of bacteria 
at the genus level. Elevated and 
reduced levels are indicated by 
direction of the arrows
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found to be associated with chronic inflammation and poor 
metabolic control [36]. Its levels have been reported to be 
associated with blood markers of inflammation (C-reactive 
protein, CRP) and endotoxemia (lipopolysaccharide-binding 
protein, LBP) in Type 1 diabetes [37]. Subdoligranulum is 
also reported to inhibit fermentation of inulin by bifidogenic 
bacteria in colon, which is considered beneficial in the pre-
vention of colon cancer [38]. Oscillibacter are known to 
produce anti-inflammatory metabolites and have effect on 
the maintenance of gut barrier integrity in mice [39]. Their 
abundance is reported to be affected by the presence of other 
gut bacteria [5]. Reduced abundance of Lachnoclostridium 
has been reported in stools of Hashimoto’s thyroiditis 
patients [40]. Increased abundance of Ruminococcus, seen 
exclusively in gastric neoplasms in our study, is reported 
in prediabetic patients and associated with impaired fasting 
plasma glucose, BMI, and waist circumference [41]. Moreo-
ver, their higher abundance has been reported in stools of 
high fat diet-induced obese rats compared to lean rats [42].
On the other hand, in patients with rectal neoplasms, Bifi-
dobacterium had significantly lower abundance as compared 
to healthy individuals in our study. These bacteria have a 
role in maintenance of healthy gut bacterial profile by inhib-
iting growth of pathogens by competitive exclusion; immune 
function; breakdown of indigestible food component by 
enzyme secretion; and folate synthesis in gut (reviewed in 
O’Callaghan et al. 2016) [43].
In patients with neoplasms of the small intestine, higher 
abundance of Enterobacteriaceae and lower abundance of 
Lachnoclostridium were similar to those seen in stomach. 
Patients with pancreatic neoplasms showed, in our study, 
a similarly low abundance of Lactobacillaceae as seen in 
those with colon neoplasms and also decreased abundance 
of Parabacteroides. Gut Parabacteroides distasonis is 
reported to have anti-inflammatory and anticancer role, 
acting through reducing TLR4 signaling/Akt activation in 
mice [44], and TLRs are known to play a significant role 
in various pancreatic diseases, including pancreatic cancer 
[45]. Robust conclusions could not be drawn regarding the 
pancreatic and small intestinal neoplasm groups due to their 
small sample size.
The gut microbiota is diverse and highly individual 
[46]. Changes in microbiota richness have been reported 
in association with cancer development [47], whereas 
reduced alpha diversity and richness in the gut micro-
biota have been linked with a Western or urban lifestyle 
[7] and compromised health in humans [48], as well as 
with colon cancer in mouse models [49]. There are also 
reports of increased richness and diversity at the taxo-
nomic and functional levels linked to gastrointestinal 
cancers [50]. We did not observe significant differences 
among the groups with respect to alpha diversity or taxo-
nomic richness. The increased levels of Enterobacteriaceae 
and Subdoligranulum in overall GIT neoplasms could, 
however, indicate increase in more pathogenic bacteria 
in GIT neoplasms. Altered abundance of most of the bac-
terial genera seen in individual gastric, colon, or rectal 
neoplasm groups was also seen in the overall non-treated 
GIT neoplasm group, suggesting that a similar pattern 
of changes in bacterial abundance is related to develop-
ment of neoplastic growth in GIT with certain taxa hav-
ing more profound effect in certain specific GIT locations. 
Chronic inflammation, obesity, and high BMI are some of 
the common risk factors associated with gastric and colon 
neoplasms.
Whereas the heterogeneity of histological subtypes of 
the tumors and the small sample size of each subtype form 
limitations for statistical conclusions, this is, to the best of 
our knowledge, the first study investigating the differences 
in microbiota in different GIT tumor locations. The number 
of controls was 13, which is similar to the number of patients 
in each neoplasm subgroup. One limitation in our study is 
that the healthy control group is on average younger than 
the patient groups. Therefore, some of the differences in 
the healthy controls could be associated with their younger 
mean age. However, the different patient groups had rela-
tively similar mean ages, and hence not a likely confounder 
in our key analysis task, which was the analysis of differ-
ences between the taxonomic compositions in fecal samples 
between the different patient groups.
Our comparison of bacterial profiles in the patient groups 
(irrespective of tumor site) collected before start of any 
treatment (non-treated) and those collected after treatment 
showed higher abundance of Lactobacillaceae at family level 
and Lactobacillus at genus level in the treated group com-
pared to the whole non-treated group. Since the abundance 
of Lactobacillaceae was significantly lower in colon cancer 
patients and those with pancreatic cancer, the higher level of 
Lactobacillaceae in treated patients compared to non-treated 
patients could indicate a recovery or growth of normal ben-
eficial bacteria after the treatment. Even though treatment 
types in the treated neoplasm group were heterogeneous, it is 
tempting to speculate that the results may indicate efficacy of 
the treatment regardless of type of treatment, tumor location, 
or histological subtype of the tumor.
In conclusion, we found significant differences in the 
abundances of specific bacterial taxonomic groups in stool 
specimens from patients with various GIT neoplasms; the 
differences were dependent on the location of neoplasia 
in the GIT. This finding could be of significance in the 
future as a tool for assessing neoplastic alterations in dif-
ferent parts of the GIT. Studies on the stool abundances 
of Lactobacillaceae, Bifidobacteriaceae, and Enterobacte-
riaceae could potentially lead to the development of a non-
invasive approach to GIT disease monitoring and treatment 
follow-up.
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